In vitro and in vivo dose delivery characteristics of large porous particles for inhalation

被引:62
作者
Dunbar, C
Scheuch, G
Sommerer, K
DeLong, M
Verma, A
Batycky, R
机构
[1] Alkermes Inc, Cambridge, MA 02139 USA
[2] InAMed GmbH, D-82131 Gauting, Germany
[3] Alkermes Europe Ltd, Cambridge CB5 8RE, England
关键词
large porous particles; lung deposition; inhalation;
D O I
10.1016/S0378-5173(02)00349-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to evaluate the in vitro and in vivo dose delivery characteristics of two large porous particle placebo formulations with different mass median aerodynamic diameters (MMAD approximately equal to 3 and 5 mum). In vitro dose delivery characteristics were measured using the multistage liquid impinger (MSLI). In vitro lung deposition was predicted by calculating the extrathoracic deposition using the ICRP model, with the remaining fraction assumed to deposit in the lungs. Healthy subjects were trained to inhale through the AIR(TM) delivery system at a target peak inspiratory flock rate (PIFR) of 60 1/min. The in vivo dose delivery of large porous particles were obtained by gamma-scintigraphy and was characterized by high ( similar to 90%), reproducible emitted doses for both the small and large MMAD powders. The mean in vivo lung deposition relative to the total metered dose were 59.0 and 37.3% for 3 and 5 pm MMAD powders, respectively, The AIR(TM) delivery system produced high in vivo lung deposition and low intersubject CVs (approximately 14%) across the range of PIFRs obtained in the study (50-80 1/min), This is relative to a variety of dry powder inhalers (DPI) that have been published in the literature. with in vivo lung deposition ranging from 13 to 35% with intersubject CVs ranging from 17 to 50%. The ICRP model provided a good estimate of the mean in vivo lung deposition for both powders. Intersubject variability was not captured by the ICRP model due to intersubject differences in the morphology and physiology of the oropharyngeal region. The ICRP model was used to predict the regional lung deposition, although these predictions were only considered speculative in the absence of experimental validation. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:179 / 189
页数:11
相关论文
共 28 条
  • [1] [Anonymous], 1994, HUM RESP TRACT MOD R
  • [2] [Anonymous], 1994, RESP DRUG DELIVERY
  • [3] Design, validation and initial testing of the Electronic Lung™ Device
    Burnell, PKP
    Malton, A
    Reavill, K
    Ball, MHE
    [J]. JOURNAL OF AEROSOL SCIENCE, 1998, 29 (08) : 1011 - 1025
  • [4] Particle deposition in a cast of human oral airways
    Cheng, YS
    Zhou, Y
    Chen, BT
    [J]. AEROSOL SCIENCE AND TECHNOLOGY, 1999, 31 (04) : 286 - 300
  • [5] CLARK AR, 1996, RESP DRUG DELIVERY, V5, P221
  • [6] Evaluation of probability density functions to approximate particle size distributions of representative pharmaceutical aerosols
    Dunbar, CA
    Hickey, AJ
    [J]. JOURNAL OF AEROSOL SCIENCE, 2000, 31 (07) : 813 - 831
  • [7] Large porous particles for pulmonary drug delivery
    Edwards, DA
    Hanes, J
    Caponetti, G
    Hrkach, J
    BenJebria, A
    Eskew, ML
    Mintzes, J
    Deaver, D
    Lotan, N
    Langer, R
    [J]. SCIENCE, 1997, 276 (5320) : 1868 - 1871
  • [8] FAN S, 2000, INT J PHARM, V198, P63
  • [9] Validating deposition models in disease: What is needed?
    Finlay, WH
    Lange, CF
    Li, WI
    Hoskinson, M
    [J]. JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2000, 13 (04): : 381 - 385
  • [10] Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates
    Finlay, WH
    Gehmlich, MG
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 210 (1-2) : 83 - 95